Skip Navigation


Annals of Oncology Advance Access originally published online on December 6, 2005
Annals of Oncology 2006 17(3):409-414; doi:10.1093/annonc/mdj096
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/3/409    most recent
mdj096v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (19)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Coudert, B. P.
Right arrow Articles by Fumoleau, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coudert, B. P.
Right arrow Articles by Fumoleau, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial

B. P. Coudert1,*, L. Arnould1, L. Moreau2, P. Chollet3, B. Weber4, L. Vanlemmens5, C. Moluçon1, N. Tubiana6, S. Causeret1, J.-L. Misset7, S. Feutray1, D. Mery-Mignard8, J. Garnier9 and P. Fumoleau1

1 Oncology, Surgery, Radiology CAC GF Leclerc, Dijon; 2 Oncology, Clinique des Domes, Clermont Ferrand; 3 Oncology, CAC J Perrin, Clermont Ferrand; 4 Oncology, CAC A Vautrin, Nancy; 5 Oncology, CAC O Lambret, Lille; 6 Oncology, CHU, Limoges; 7 Oncology, Hal St Louis, Paris; 8 Oncology, Sanofi-Aventis, Paris; 9 Oncology, Roche, Neuilly sur Seine, France

* Correspondence to: Dr B. P. Coudert, Centre GF Leclerc, 1 rue du Pr Marion, 21000 Dijon, France. Tel: +33-380-737-720; Fax: +33-380-737-712; E-mail: bcoudert{at}dijon.fnclcc.fr

Background: Trastuzumab plus chemotherapy has become the standard of care for women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. Trastuzumab-based pre-operative systemic (neo-adjuvant) therapy (PST) also appears promising, warranting further investigation.

Patients and methods: Patients with HER2-positive, stage II/III non-inflammatory, operable breast cancer requiring a mastectomy (but who wished to conserve the breast) received weekly trastuzumab and 3-weekly docetaxel for six cycles before surgery. The primary end point was pathological complete response (pCR) rate, determined from surgical specimens.

Results: Thirty-three patients were enrolled. The majority (79%) had T2 tumors, with 42% being N1/2. Twenty-nine patients completed six cycles of therapy and one patient withdrew prematurely due to progressive disease. A complete or partial objective clinical response was seen in 96% (73% and 23%, respectively) of patients. Surgery was performed in 30 patients, breast conserving in 23 (77%). In an intention-to-treat analysis, tumor and nodal pCR was seen in 14 (47%) patients. Treatment was generally well tolerated. Grade 3/4 neutropenia occurred in 85% of patients while febrile neutropenia was encountered in 18%. Only three patients withdrew prematurely due to toxicity. No symptomatic cardiac dysfunction was reported.

Conclusions: PST with trastuzumab plus docetaxel achieved promising efficacy, with a high pCR rate and good tolerability, in women with stage II or III HER2-positive breast cancer.

Key words: breast cancer, docetaxel, efficacy, neo-adjuvant treatment, safety, trastuzumab


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
J. M. Park, M. Terabe, J. C. Steel, G. Forni, Y. Sakai, J. C. Morris, and J. A. Berzofsky
Therapy of Advanced Established Murine Breast Cancer with a Recombinant Adenoviral ErbB-2/neu Vaccine
Cancer Res., March 15, 2008; 68(6): 1979 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff
Locally Advanced and Inflammatory Breast Cancer
J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790.
[Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
A. Saad, R. Beto, J. Abraham, and S. C. Remick
Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents
ASCO Educational Book, January 1, 2008; 2008(1): 428 - 434.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Arnould, P. Arveux, J. Couturier, M. Gelly-Marty, C. Loustalot, F. Ettore, C. Sagan, M. Antoine, F. Penault-Llorca, B. Vasseur, et al.
Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification
Clin. Cancer Res., November 1, 2007; 13(21): 6404 - 6409.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al.
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Penault-Llorca, C. Abrial, M.-A. Mouret-Reynier, I. Raoelfils, X. Durando, M. Leheurteur, P. Gimbergues, J. Tortochaux, H. Cure, and P. Chollet
Achieving Higher Pathological Complete Response Rates in HER-2-Positive Patients With Induction Chemotherapy Without Trastuzumab in Operable Breast Cancer
Oncologist, April 1, 2007; 12(4): 390 - 396.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.